Evolving Landscape of ADT in Prostate Cancer
Type
Webinar
EVENT DETAILS
Display Date
Monday April 15, 2024
Display Date Line 2
7 pm ET
Location
Virtual
Speaker
Moderator: Fred Saad // Speakers: Andrew Loblaw & Ricardo Rendon
ACCREDITATION
Accreditation
Section 1 Group Learning Credits
Event Description
Moderator: Fred Saad
Speakers: Andrew Loblaw & Ricardo Rendon
OBJECTIVES
By participating in this learning program, healthcare providers can expect to:
- Describe the role of Androgen Deprivation Therapy (ADT) from a multidisciplinary perspective and apply advanced prostate cancer treatment strategies that take into consideration the risks and benefits of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists.
- Evaluate the benefits and limitations of available ADT options (luteinizing hormone–releasing hormone [LHRH] agonists, gonadotropin-releasing hormone [GnRH] agonists and antagonists) for patients with advanced prostate cancer according to clinical efficacy, CV risk, mechanism of action, route of administration and other practical considerations.
- Design and integrate an individualized treatment plan that includes the most appropriate ADT according to clinical considerations and patient preferences at various stages of the prostate cancer disease continuum, including:
- High risk localized disease
- Biochemical recurrence
- Newly diagnosed metastatic hormone sensitive
Simultaneous interpretation from English to French will be available
Footer
ACCREDITATION
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.
_______________________________________________________
